Table 4.
Changes in echocardiographic parameters in the pooled heart failure population
| Baseline observed (n = 50) | 6‐month active therapy | 12‐month active therapy | |||
|---|---|---|---|---|---|
| Observed (n = 43) | Paired change from baseline (n = 43) | Observed (n = 41) | Paired change from baseline (n = 41) | ||
| Left ventricular ejection fraction (%)* | 31.6 ± 8.5 (50) 31.0 [26.0–38.0] | 31.2 ± 9.9 (43) 30.0 [23.0–40.0] | 0.0 ± 5.9 (43) 1.0 [–4.0 to 4.0] P = 0.834 | 34.8 ± 12.4 (41) 32.0 [24.0–44.0] | 3.3 ± 7.6 (41) 4.0 [–1.0 to 8.0] P = 0.004 |
| Left ventricular end‐systolic volume (mL)* | 119.7 ± 63.6 (50) 109.0 [70.0–150.0] | 123.4 ± 69.4 (43) 122.0 [65.0–157.0] | 3.9 ± 32.3 (43) –5.0 [–14.0 to 17.0] P = 0.943 | 111.3 ± 68.4 (41) 100.0 [60.0–140.0] | –6.0 ± 27.5 (41) –6.0 [–21.0 to 5.0] P = 0.078 |
| Left ventricular end‐diastolic volume (mL)* |
169.3 ± 71.7 (50) 161.5 [110.0–219.0] |
172.5 ± 81.0 (43) 169.0 [105.0–212.0] |
4.6 ± 38.5 (43) –3.0 [−19.0 to 20.0] P = 0.966 |
161.4 ± 75.9 (41) 146.0 [103.0–200.0] | –4.3 ± 31.1 (41) –7.0 [–27.0 to 9.0] P = 0.288 |
Values are mean ± standard deviation (n), or median [interquartile range].
*
Nominal two‐sided P‐value from Wilcoxon signed‐rank test for change from baseline.